What is the Demand for Recombinant Insulin Therapeutics in the Global Market?

Introduction

Human Recombinant Insulin Market is segmented by product type (short-acting human insulin, intermediate-acting human insulin and premixed human insulin), brand (Insuman, Humulin, Novolin, and other brands), distribution channel (retail pharmacies and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

The Human Recombinant Insulin Market has been growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e., 2020 to 2027. The factors such as market dynamics, involving the drivers, restraints, opportunities, and challenges through which the impact of these factors in the market are outlined.

The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Human Recombinant Insulin Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.

Human Recombinant Insulin Market size was valued at USD 31.35 billion in 2020 and is projected to reach USD 54.79 billion by 2028, growing 7.25% from 2021 to 2028. The rise in the number of diabetic patients and the growing medical reimbursement setup across different regions are the key factors driving the growth of the global Human Recombinant Insulin Market.

The advancement in activities of research and development by various government and private organizations is expected to propel the growth of the market. The increase in investments in diabetes research activities has resulted in influencing the demand for the market. Moreover, the recombinant insulin market is following a small-scale process for development by offering analog products coupled with custom media formulations owing to promote market growth. The Global Human Recombinant Insulin Market report provides a holistic evaluation of the market.

Global Human Recombinant Insulin Market Overview

The Human Recombinant Insulin Market is expected to grow owing to the increase in several diabetic patients. The favorable medical reimbursement in emerging nations helping to reduce the risk factors leading to diabetes is another key factor responsible for market growth. The growing geriatric population expected patent expiry of mainly human analog drugs is expected to promote the growth of the market.

These market estimates have been considered by studying the impact of various social, political, and economic factors along with the current market dynamics affecting the Human Recombinant Insulin Market growth.

The market dynamics include a Porter’s Five Forces analysis which explains the five forces: namely buyers’ bargaining power, suppliers’ bargaining power, the threat of new entrants, the threat of substitutes, and the degree of competition in the Human Recombinant Insulin Market. It explains the various participants, such as system integrators, intermediaries, and end-users within the ecosystem of the market.

Global Human Recombinant Insulin Market Definition

Recombinant insulin is one of the first products of biotechnology. Recombinant insulin is synthetic insulin obtained by utilizing recombinant DNA technology. They replace the animal insulins and semisynthetic insulin resulted from the modification of animal insulins. These are created to supply the need for a consistent and sufficient worldwide demand. Insulin replacement therapy is the standard of care for patients with type 1 and types 2 diabetes mellitus.

With the advancement in recombinant DNA technology, recombinant human insulin became available in huge amounts. This is provided by biosynthesis in microorganisms. These have a superior level of purity and consistent quality as compared with synthetic insulin. Patients with diabetes can be safely and effectively transferred from animal and semisynthetic human insulin to recombinant human insulin with no change expected in insulin dose.

Global Human Recombinant Insulin Market: Segmentation Analysis

The Global Human Recombinant Insulin Market is segmented based on Product, Distribution Channel, and Geography.

Human Recombinant Insulin Market Based on Product

• Regular (short-acting) insulin
• NPH (intermediate-acting) insulin
• Premixed human insulins insulin

The regular (short-acting) insulin is anticipated to witness the highest growth of the market. These insulins are mainly consumed before meals and are gaining popularity around the globe.

Human Recombinant Insulin Market based on Distribution Channel

• Hospitals
• Retail pharmacies
• Online pharmacies
• Others

Retail pharmacies are expected to hold the highest share of the market owing to their growing adoption rate of human insulin delivery systems. The growing technological advancement of insulin injectables has resulted in the growth of the retail pharmacies segment. The growing number of retail pharmacies across developing and developed countries have anticipated the growth of the market.

Human Recombinant Insulin Market Based on Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

North America is one of the largest growing regions owing to the increasing technological developments in insulin delivery products.

Conclusion

Recombinant Human Insulin Therapy is a confirmed and effective therapeutic option when supported by appropriate patient education. Clinical awareness of any changes in insulin quality is very important. Self-monitoring of blood glucose for several weeks after a change to or between biosimilar insulins will help to identify any differences, thus enabling dose adaptation.

Dialectologists are fully aware that patients' insulin requirements change under different real-life situations, and they should take this into consideration. Therefore, individual guidance, counseling, and monitoring often, remain an essential requirement to achieve better and safer glycemic control, especially in patients requiring insulin therapy. Global availability of recombinant human insulin of consistently high quality is an important future step in the quest to improve the outcome for people with diabetes.